Shattuck Labs, Inc. (STTK)
Largest Insider Buys in Sector
STTK Stock Price History Chart
STTK Stock Performance
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Insider Activity of Shattuck Labs, Inc.
Over the last 12 months, insiders at Shattuck Labs, Inc. have bought $126,999 and sold $369,558 worth of Shattuck Labs, Inc. stock.
On average, over the past 5 years, insiders at Shattuck Labs, Inc. have bought $39.91M and sold $12.26M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schreiber Taylor (Chief Executive Officer) — $94,231. Brous Tyler (director) — $32,768.
The last purchase of 36,500 shares for transaction amount of $44,220 was made by Schreiber Taylor (Chief Executive Officer) on 2024‑10‑07.
List of Insider Buy and Sell Transactions, Shattuck Labs, Inc.
| 2024-10-07 | Chief Executive Officer | 36,500 0.0249% | $1.21 | $44,220 | +11.50% | |||
| 2024-06-28 | director | 3,000 0.0065% | $3.90 | $11,700 | 0.00% | |||
| 2024-06-27 | director | 5,416 0.0117% | $3.89 | $21,068 | 0.00% | |||
| 2024-06-26 | Chief Executive Officer | 14,400 0.0278% | $3.47 | $50,011 | -12.93% | |||
| 2024-03-06 | Sale | See Remarks | 11,354 0.0266% | $10.53 | $119,558 | -50.42% | ||
| 2024-01-10 | Sale | Chief Financial Officer | 25,000 0.0527% | $10.00 | $250,000 | -25.10% | ||
| 2022-04-26 | 28,330 0.0665% | $3.63 | $102,838 | -16.16% | ||||
| 2022-04-21 | 26,049 0.0621% | $3.69 | $96,121 | -15.89% | ||||
| 2022-01-19 | director | 3,000 0.0073% | $6.87 | $20,610 | -48.05% | |||
| 2022-01-18 | director | 2,500 0.0061% | $7.01 | $17,525 | -48.97% | |||
| 2022-01-14 | director | 2,500 0.0058% | $7.16 | $17,900 | -52.05% | |||
| 2021-10-19 | Sale | General Counsel | 33,000 0.0774% | $19.50 | $643,500 | -78.12% | ||
| 2021-07-15 | Sale | director | 34 <0.0001% | $22.74 | $773 | -67.34% | ||
| 2021-07-15 | Sale | General Counsel | 2,000 0.0047% | $22.18 | $44,367 | -67.34% | ||
| 2021-07-15 | Sale | Chief Financial Officer | 2,000 0.0047% | $22.13 | $44,263 | -67.34% | ||
| 2021-07-14 | Sale | director | 12,049 0.0289% | $23.14 | $278,784 | -68.01% | ||
| 2021-07-13 | Sale | director | 4,356 0.0103% | $25.12 | $109,426 | -70.64% | ||
| 2021-07-12 | Sale | director | 2,829 0.0067% | $26.15 | $73,983 | -71.36% | ||
| 2021-07-09 | Sale | director | 3,276 0.0077% | $26.54 | $86,935 | -71.55% | ||
| 2021-07-08 | Sale | director | 3,586 0.0084% | $26.24 | $94,101 | -70.89% |
Insider Historical Profitability
| Brous Tyler | director | 238088 0.4987% | $1.10 | 5 | 0 | <0.0001% |
| Schreiber Taylor | Chief Executive Officer | 71002 0.1487% | $1.10 | 2 | 10 | |
| Redmile Group, LLC | 5619914 11.772% | $1.10 | 1 | 0 | +49.69% | |
| Golumbeski George | 54613 0.1144% | $1.10 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Fidelity Investments | $63.66M | 14.98 | 7.12M | +0.71% | +$446,758.62 | <0.01 | |
| Redmile Group | $50.2M | 11.81 | 5.62M | -0.08% | -$39,559.50 | 0.51 | |
| Prosight Management Lp | $33.3M | 7.83 | 3.73M | +33.86% | +$8.42M | 9.28 | |
| Adage Capital Partners Gp L L C | $21.19M | 4.98 | 2.37M | +35.22% | +$5.52M | 0.04 | |
| The Vanguard Group | $16.27M | 3.83 | 1.82M | +38.18% | +$4.5M | <0.0001 |